Association of Periodontal Disease with Serum Uric Acid and CRP in Patients Treated for Acute Coronary Syndrome: A Comparative Study

2021 ◽  
Vol 19 (8) ◽  
pp. 07-12
Author(s):  
Mohammed Ihsan Chabuk ◽  
Ahmed Mahdi Sharba ◽  
Ali Razzaq Alisalih Alsafar
Keyword(s):  
Acute Coronary Syndrome ◽  
Comparative Study ◽  
Periodontal Diseases ◽  
Vascular Inflammation ◽  
Coronary Vessels ◽  
Acute Phase Reactant ◽  
Severe Form ◽  
Blood Analysis ◽  
Coronary Syndrome ◽  
The Impact

Background: Periodontal diseases (PED) are a widespread, complicated, long-lasting inflammation of the gum. In recent years, lots of lines of evidence have confirmed the existence of an interrelated link between PED and systemic illnesses including acute coronary syndrome (ACS). In the pathogenesis of ACS, the persuasive inflammatory role of coronary vessels is well documented. An increasing body of evidence highlights the impact of UA in inflammation. C-reactive protein (CRP) is an acute phase reactant well-known as a nonspecific marker for systemic and vascular inflammation. The study intended to evaluate the associations of PED with SUA and CRP in patients treated for ACS in a comparative study. Methodology: 136-patients registered in this comparative study labeled as ACS besides 74-controls. The blood analysis of creatinine, urea, SUA and CRP had done for the applicants. Oral examination for grades and severity of PED had performed, and the candidates were grouped accordingly. Statistical studies had attained using SPSS software (IBM), with a significance-value calculated at <0.05. Results: There was a significantly higher HSCRP levels with a higher nonsignificant SUA levels among the ACS group. Risk factors in terms of incidence of DM, hypertension, and smoking (except the BMI) were significantly higher among patients. More than 3/4th of the patients' group was suffering from generalized PED (74.3%), while 15.4% had a localized PED and only 9% had healthy periodontium. Meanwhile, about 2/3rd of the controls has normal periodontium. 18.4% vs. 75% had a mild, 25.7% vs. 4% had a moderate, and 21.3% vs. zero had a severe form of PED, in patients and control respectively. There was a significant worsening of PED in terms of severity and grading (p-0.001) with the increase of HSCRP levels, which is not the case for increased SUA. Conclusion: HSCRP levels were significantly higher among patients with ACS compared to healthy control. There was a significant worsening of PED in terms of severity and grading with the increase of HSCRP levels. This is not the case for increased SUA, which is not associated with poor periodontal status.

scholarly journals Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?

2021 ◽  
Vol 8 (1) ◽  
pp. e000840
Author(s):  
Lianne Parkin ◽  
Sheila Williams ◽  
David Barson ◽  
Katrina Sharples ◽  
Simon Horsburgh ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Clinical Practice ◽  
Real World ◽  
Chronic Obstructive ◽  
Treatment Intensification ◽  
Cardiovascular Comorbidity ◽  
Coronary Syndrome ◽  
Long Acting ◽  
The Impact

BackgroundCardiovascular comorbidity is common among patients with chronic obstructive pulmonary disease (COPD) and there is concern that long-acting bronchodilators (long-acting muscarinic antagonists (LAMAs) and long-acting beta2 agonists (LABAs)) may further increase the risk of acute coronary events. Information about the impact of treatment intensification on acute coronary syndrome (ACS) risk in real-world settings is limited. We undertook a nationwide nested case–control study to estimate the risk of ACS in users of both a LAMA and a LABA relative to users of a LAMA.MethodsWe used routinely collected national health and pharmaceutical dispensing data to establish a cohort of patients aged >45 years who initiated long-acting bronchodilator therapy for COPD between 1 February 2006 and 30 December 2013. Fatal and non-fatal ACS events during follow-up were identified using hospital discharge and mortality records. For each case we used risk set sampling to randomly select up to 10 controls, matched by date of birth, sex, date of cohort entry (first LAMA and/or LABA dispensing), and COPD severity.ResultsFrom the cohort (n=83 417), we identified 5399 ACS cases during 281 292 person-years of follow-up. Compared with current use of LAMA therapy, current use of LAMA and LABA dual therapy was associated with a higher risk of ACS (OR 1.28 (95% CI 1.13 to 1.44)). The OR in an analysis restricted to fatal cases was 1.46 (95% CI 1.12 to 1.91).ConclusionIn real-world clinical practice, use of two versus one long-acting bronchodilator by people with COPD is associated with a higher risk of ACS.

scholarly journals Immediate versus staged revascularisation in multivessel coronary disease: an updated meta-analysis

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
F Von Renteln ◽  
S Hassan ◽  
K Szummer ◽  
R Edfors ◽  
D Venetsanos ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Disease ◽  
Controlled Trial ◽  
Interventional Treatment ◽  
Index Hospitalisation ◽  
Coronary Syndrome ◽  
Coronary Interventions ◽  
Baseline Characteristics ◽  
Meta Regression ◽  
The Impact

Abstract Background Percutaneous coronary interventions (PCIs) are often aimed at the culprit vessel in acute coronary syndromes (ACSs) followed by revascularisation of other stenoses later in the index hospitalisation or shortly after discharge. PCI delay of non-culprit coronary vessels stenoses is supported by lower contrast fluid use and thrombocyte aggregation. Distinct coronary interventions increase the risk of both non- and coronary artery complications, e.g. acute abdominal and periphery artery bleeding, suggesting undertaking all PCIs at the same time. Purpose To assess the effect on mortality and re-myocardial infarction (MI) of immediate versus staged revascularisation in multivessel coronary disease, with the latter constrained to initial PCI of the culprit coronary vessel. Methods The syntax of “randomised controlled trial (RCT) & acute coronary syndrome & complete revascularisation” was undertaken in PubMed. Clinical characteristics were gathered at the index hospitalisation. The intervention scenario was acute coronary syndrome or not. Meta-analyses calculated relative risk (RR) reductions on outcomes of 1) mortality and 2) re-MI. Meta-regression assessed linear difference between interventional treatment benefits and baseline characteristics. Results A total of 148 studies was found. Of those, 8 was found eligible for further analyses and their baseline characteristics are shown in Table 1. Comparison of immediate versus staged revascularisation on mortality was nonsignificant (RR, 1.19; 95% CI: 0.78–1.81, p=0.43) (Figure 1). The impact of Immediate vs staged revascularisation on re-MI was also nonsignificant (RR, 0.83; 95% CI: 0.44–1.55, p=0.56). Meta-regression found no associations between the outcomes and study characteristics (not shown). Conclusion The intervention of immediate compared to staged revascularisation assessed on outcomes of all-cause mortality and re-MI were nonsignificant. Figure 1 Funding Acknowledgement Type of funding source: None

scholarly journals Impact of timing of randomization after an acute coronary syndrome and subsequent events in patients with type 2 diabetes mellitus: an analysis of the EXAMINE trial

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Elharram ◽  
A Sharma ◽  
W White ◽  
G Bakris ◽  
P Rossignol ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Type 2 Diabetes Mellitus ◽  
Acute Coronary Syndrome ◽  
Primary Outcome ◽  
Funding Source ◽  
Coronary Syndrome ◽  
The Impact

Abstract Background The timing of enrolment following an acute coronary syndrome (ACS) may influence cardiovascular (CV) outcomes and potentially treatment effect in clinical trials. Using a large contemporary trial in patients with type 2 diabetes mellitus (T2DM) post-ACS, we examined the impact of timing of enrolment on subsequent CV outcomes. Methods EXAMINE was a randomized trial of alogliptin versus placebo in 5380 patients with T2DM and a recent ACS. The primary outcome was a composite of CV death, non-fatal myocardial infarction [MI], or non-fatal stroke. The median follow-up was 18 months. In this post hoc analysis, we examined the occurrence of subsequent CV events by timing of enrollment divided by tertiles of time from ACS to randomization: 8–34, 35–56, and 57–141 days. Results Patients randomized early (compared to the latest times) had less comorbidities at baseline including a history of heart failure (HF; 24.7% vs. 33.0%), prior coronary artery bypass graft (9.6% vs. 15.9%), or atrial fibrillation (5.9% vs. 9.4%). Despite the reduced comorbidity burden, the risk of the primary outcome was highest in patients randomized early compared to the latest time (adjusted hazard ratio [aHR] 1.47; 95% CI 1.21–1.74) (Figure 1). Similarly, patients randomized early had an increased risk of recurrent MI (aHR 1.51; 95% CI 1.17–1.96) and HF hospitalization (1.49; 95% CI 1.05–2.10). Conclusion In a contemporary cohort of T2DM with a recent ACS, early randomization following the ACS increases the risk of CV events including recurrent MI and HF hospitalization. This should be taken into account when designing future clinical trials. Figure 1 Funding Acknowledgement Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Takeda Pharmaceutical

scholarly journals 68 The impact of the weekend admission on early mortality after acute coronary syndrome: a meta-analysis of observational studies

Heart ◽  
2017 ◽  
Vol 103 (Suppl 5) ◽  
pp. A51-A52
Author(s):  
Chun Shing Kwok ◽  
Mohammed Al-Dokheal ◽  
Sami Aldaham ◽  
Claire Rushton ◽  
Robert Butler ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Observational Studies ◽  
Meta Analysis ◽  
Early Mortality ◽  
Coronary Syndrome ◽  
The Impact

scholarly journals INCREASED INCIDENCE OF ACUTE CORONARY SYNDROME FOLLOWING HURRICANE KATRINA IN NEW ORLEANS: THE IMPACT CONTINUES

2013 ◽  
Vol 61 (10) ◽  
pp. E12
Author(s):  
John Moscona ◽  
Sumit Tiwari ◽  
Kevin DeAndrade ◽  
Henry Quevedo ◽  
Matthew Peters ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Hurricane Katrina ◽  
New Orleans ◽  
Coronary Syndrome ◽  
The Impact

scholarly journals The impact of Mediterranean diet on coronary plaque vulnerability, microvascular function, inflammation, and microbiome after an acute coronary syndrome: study protocol for the MEDIMACS randomized, controlled, mechanistic clinical trial.

2021 ◽  
Author(s):  
Ana I Fernandez ◽  
Javier Bermejo ◽  
Raquel Yotti ◽  
Miguel Ángel Martínez-Gonzalez ◽  
Alex Mira ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Acute Coronary Syndrome ◽  
Mediterranean Diet ◽  
Atherosclerotic Plaque ◽  
High Intensity ◽  
Plaque Vulnerability ◽  
Diet Intervention ◽  
Coronary Syndrome ◽  
Randomized Controlled ◽  
The Impact

Abstract Background: Primary prevention trials have demonstrated that the traditional Mediterranean diet is associated with a reduction in cardiovascular mortality and morbidity. However, this benefit has not been proven for secondary prevention after an acute coronary syndrome (ACS). We hypothesized that a high-intensity Mediterranean diet intervention after an ACS decreases the vulnerability of atherosclerotic plaques by complex interactions between anti-inflammatory effects, microbiota changes and modulation of gene expression. Methods: The MEDIMACS project is an academically funded, prospective, randomized, controlled and mechanistic clinical trial designed to address the effects of an active randomized intervention with the Mediterranean diet on atherosclerotic plaque vulnerability, coronary endothelial dysfunction, and other mechanistic endpoints. One hundred patients with ACS are randomized 1:1 to a monitored high-intensity Mediterranean diet intervention or to standard-of-care arm. Adherence to diet is assessed in both arms using food frequency questionnaires and biomarkers of compliance. The primary endpoint is the change (from baseline to 12 months) in the thickness of the fibrous cap of a non-significant atherosclerotic plaque in a non-culprit vessel, as assessed by repeated optical-coherence-tomography intracoronary imaging. Indices of coronary vascular physiology and changes in gastrointestinal microbiota, immunological status, and protein and metabolite profiles will be evaluated as secondary endpoints. Discussion: The results of this trial will address the key effects of dietary habits on atherosclerotic risk and will provide initial data on the complex interplay of immunological, microbiome-, proteome- and metabolome-related mechanisms by which non-pharmacological factors may impact the progression of coronary atherosclerosis after an ACS.Trial registration: ClinicalTrials.gov, NCT03842319. Registered on 13 May 2019. https://clinicaltrials.gov/ct2/show/NCT03842319

Cardiac Rehabilitation after an Acute Coronary Syndrome: The Impact in Elderly Patients

Cardiology ◽  
2015 ◽  
Vol 131 (3) ◽  
pp. 177-185 ◽  
Author(s):  
Patrícia Rodrigues ◽  
Mário Santos ◽  
Maria João Sousa ◽  
Bruno Brochado ◽  
Diana Anjo ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiac Rehabilitation ◽  
Functional Capacity ◽  
Heart Rate Recovery ◽  
Real Life ◽  
The Elderly ◽  
Chronotropic Response ◽  
Coronary Syndrome ◽  
Supervised Exercise ◽  
The Impact

Introduction: Cardiac rehabilitation (CR) has been shown to decrease mortality and morbidity, improve the control of risk factors and the quality of life of patients with coronary artery disease. However, the elderly are underrepresented in most studies and in real-life CR programs. Our goal was to evaluate the impact of CR after an acute coronary syndrome in the elderly population. Methods: A cutoff of 65 years was used to dichotomize age. Our main focus was on the effects of ambulatory supervised exercise training on several surrogate markers, namely total cholesterol, low- and high-density lipoprotein cholesterol, triglycerides, body mass index, fasting glucose, glycated hemoglobin, probrain natriuretic peptide, International Physical Activity Questionnaire score, maximal exercise capacity, chronotropic response index and heart rate recovery. We evaluated those variables at the beginning and at the end of phase II of the CR program (after 3 months) and repeated the treadmill test at 12 months. Results: A total of 548 patients with a recent acute coronary syndrome were enrolled; 37% were 65 years old or older. Both age groups had a statistically significant improvement in all the evaluated parameters. Interestingly, at 12 months both groups maintained the improvement in functional capacity seen immediately after 3 months. Conclusions: The benefits of CR in terms of functional capacity, metabolic profile and other prognostic parameters were significant in both younger and older patients. Therefore, all eligible patients should be referred to CR programs, irrespective of age.

Sign in / Sign up

Export Citation Format

Share Document